Cookie Consent by Free Privacy Policy Generator
EFA Prize



Rewarding the asthma and COPD digital care innovators

We are all experiencing an ongoing digital revolution that presents itself with concrete opportunities to improve the lives of people across Europe. But what are the digital tools and solutions that serve patients improve their asthma and chronic obstructive pulmonary disease (COPD)?


A Prize from patients to reward patient-centred technology for respiratory disease

To take stock of ongoing developments, EFA in 2023 launched a prize to celebrate achievements in the digital health sector that centre asthma and COPD patients’ needs from development to implementation.

EFA Patients' Digital Prize is a recognition granted by patients to reward those digital health initiatives that centre patients through their design, accessibility and efficacy. A prestigious jury has been looking at the pillars for a successful tool, and how the innovators introduce the approaches of co-creation and digital partnership between patients, healthcare providers and solution developers.


Application process 

EFA launched a call to find developers whose digital technology breaks down barriers in equity, promises security, and looks beyond controlling asthma and COPD and towards improving Quality of Life.

Terms of Reference and conditions, the submission form and the evaluation criteria are still available here.

Applications are closed.


A European recognition from patients

The winners of the EFA Patients’ Digital Prize have been invited to the award ceremony on 27 April in Ghent, Belgium in presence of EFA’s 45 patients organisations in 26 countries, to benefit from structured exchanges with the asthma and COPD patient community in Europe.

The winners have been recognised by patients at European level as forward thinkers, engaged in empowering people with asthma and COPD to improve health outcomes, and key digital health partners.

Learn more about the 2023 winning solutions and the award ceremony.


Selection process

The EFA Patients’ Digital Prize acknowledges digital technologies that fit in one of three disease-focused categories:

  • Prize for best digital technology covering asthma.
  • Prize for best digital technology covering COPD.
  • Prize for best digital technology covering both asthma & COPD.


To choose the winners of each category, a panel of individuals agreeing to the Terms of Reference for Jury Members has been selected by EFA Office in March 2023 that was composed of:

  • 1 asthma patients’ representative from EFA Members.
  • 1 COPD patients’ representative from EFA Members.
  • 1 young asthma patient from the European Allergy & Asthma Youth Parliament.
  • 1 healthcare professional from the respiratory sector.
  • 1 digital health industry expert.
  • 1 representative from the EFA Sustainable Corporate Partners (pharma) that supports the EFA DIG_IT project with unrestricted grants.


A digital seal as a recognition mark

Winners get the right to use the EFA Patients Digital Award seal for two years (until 31 December 2025) to make their achievement visible and recognisable to their customers.

asthma LD AsthmaTuner by Medituner AB AsthmaTuner is a digital medical device distributed in Sweden, Norway, Denmark and the USA. It is used as a self-management device for patients with asthma. The app allows patients to have instant and objective instructions on how to adjust treatment based on the variability of their disease. 
asthma LD RespiraSense by PMD Solutions RespiraSense is an accurate, motion tolerant and continuous respiratory rate monitor that measures chest and abdomen movement associated with the mechanics of breathing.
asthma LD NuvoAir Home from NuvoAir  NuovoAir Home is a platform designed to enable data sharing between healthcare professionals and people with long-term respiratory conditions. This allows clinicians to make faster decisions while helping patients to understand better their lung health.



The EFA’s Patients' Digital Prize is being made possible thanks to unrestricted grants from EFA’s Sustainable Corporate Partners Chiesi and Roche.